OMEGA THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
OMEGA THERAPEUTICS INC. - More news...
OMEGA THERAPEUTICS INC. - More news...
- Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
- Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings
- Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
- Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research
- Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
- Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors
- Omega Therapeutics To Participate In Two Upcoming Investor Conferences
- Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
- Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
- Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
- Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
- Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
- Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
- Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024
- Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
- Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference
- Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis
- Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- Omega Therapeutics to Participate in The Jefferies London Healthcare Conference
- Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller
- Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC
- Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD’s The Liver Meeting® 2023
- Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial
- Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26
- Omega Therapeutics to Participate in Two Upcoming Investor Conferences
- Omega Therapeutics Announces Updates to its Board of Directors
- Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
- Omega Therapeutics Appoints Chris Schade to its Board of Directors
